

宏利環球基金
可變資本投資公司
註冊辦事處：31, Z.A. Bourmicht, L-8070 Bertrange
Grand Duchy of Luxembourg

此乃重要文件，務請閣下即時垂注。閣下如有疑問，應尋求獨立的專業意見。本公司董事就本通知書所載資料的準確性承擔全部責任，並且在作出一切合理查詢後確認，就其深知及確信，並無遺漏會使任何陳述產生誤導的任何其他事實。

致股東通知書
(「通知書」)

2026年5月5日

親愛的股東：

我們茲致函通知閣下宏利環球基金（「本公司」）作出的若干更改。

除非下文另有指明，否則此等更改將反映在本公司日期將為2026年7月的經修訂售股章程（及在適用的情況下及僅就香港股東而言，則為經修訂香港說明文件）（統稱為「**經修訂售股章程**」）。本通知書概述有關更改以便閣下參考，並且應與本公司日期為2026年4月的現有售股章程（及在適用的情況下及僅就香港股東而言，則為日期為2026年4月的現有香港說明文件）（統稱為「**售股章程**」），以及（如可提供）經修訂售股章程的完整文本（其載列有關此等更改的全面及完整資料）一併閱讀。

除非另有指明，否則本通知書所用的詞語及字句的涵義與售股章程中所賦予者相同。

本公司的董事會（「**董事**」或「**董事會**」）已決定，自2026年7月10日（「**生效日期**」）起實施以下有關本公司的更改乃屬適當（除非下文另有指明）：

1. 亞洲小型公司基金重新定位

為了向投資者提供一個以迅速增長的創新及科技行業為主題焦點的產品，以獲取更具吸引力的回報，從而吸引更多投資者的資金流入以進一步擴大子基金的規模，藉此提高子基金的基金管理效率，亞洲小型公司基金的投資目標將予更改，以致子基金將旨在透過主要投資於在亞太地區註冊成立、位於亞太地區或在亞太地區上市，或在亞太地區擁有重大業務利益的創新及／或科技公司（「**亞太創新公司**」）的股票及股票相關證券，為持作長線投資並準備接受其投資價值有顯著波幅的投資者提供長期資本增長。

投資政策亦將予修訂，以致子基金最少70%的淨資產將會投資於亞太創新公司的股票及股票相關證券。

因此，子基金可能直接及／或間接投資於從事（但不限於）人工智能價值鏈、生物科技，以及半導體及相關設備的開發及生產的公司。

此外，股東應注意，自生效日起，投資政策將作出以下主要更改：

- (a) 子基金可遵照2010年法律第41(1)(e)條規定，將其最多10%的淨資產投資於UCITS（可轉讓證券集體投資計劃）及其他UCIs（集體投資計劃）；
- (b) 子基金對於其淨資產投資於任何市值的發行機構的比例將不再受任何限制（儘管基於其投資組合的本質，中小型公司證券所佔子基金淨資產的比例有時可超過30%）；

- (c) 子基金可不時將其超過30%的淨資產投資於以下行業的公司：資訊科技（包括硬件及軟件）、工業、通訊服務、非必需消費品及醫療保健；
- (d) 子基金可分別通過滬港通及深港通，不時將其超過30%的淨資產直接投資於在上交所或深交所上市的若干中國A股；及
- (e) 在市場極端波動或嚴重不利市況下，子基金將具有靈活性，可暫時將其重大部分（最多40%）的資產持有現金或現金等價物，或投資於短期貨幣市場票據，以保留子基金投資組合內資產的價值。

子基金的投資目標及政策作出更改後（「重新定位」），子基金將不再將其表現與任何基準指數作比較，亦不會參照任何基準指數進行管理。

基於重新定位，子基金將由生效日期起易名為「亞洲創新股票基金」，以反映其新的投資重點。

預期投資管理人於生效日期前約兩星期（「重新調整期」）開始重新調整子基金投資組合比重。鑑於子基金在重新定位之前和之後的投資目標及政策存在差異，預期需要重新調整比重的資產比例相當大。投資者應注意，在重新調整期內，子基金可能無法完全遵循其當前投資目標及政策。

上述重新定位將招致的法律及行政費用約為35,000美元，將由亞洲小型公司基金承擔。

2. 其他雜項更新

請亦注意經修訂售股章程（及在適用的情況下，則為香港說明文件）以下的雜項更新：

- (a) 加強售股章程附錄二（法定和一般資料）中有關潛在利益衝突的披露；
- (b) Manulife Investment Management (Europe) Limited的註冊辦事處更改為4th Floor, One Strand, London WC2N 5HR, United Kingdom；
- (c) 管理公司董事會的變動；及
- (d) 其他加強及／或簡化披露、行政、編輯及／或用於澄清的更新。

僅就亞洲小型公司基金股東而言，若閣下不同意第1節載述的更改，閣下可申請贖回或將閣下在亞洲小型公司基金中的持股轉換為任何其他子基金的相同類別或分類的股份，而無需支付任何轉換費或贖回費，直至2026年6月26日。就上文所載的其他更改而言，若閣下不同意該等更改，閣下可申請贖回或將閣下在相關子基金的持股轉換為任何其他子基金的相同類別或分類的股份，惟須根據發售文件支付轉換費，但贖回費則獲豁免。然而，閣下的銀行或財務顧問可能會就該等轉換／贖回指示向閣下收取費用。倘若閣下有任何疑問，建議閣下聯絡閣下的銀行、分銷商或財務顧問。

閣下只可將所持有的股份轉換為同一子基金或另一子基金的相同類別或分類的股份，而該等股份乃根據相關發售文件的條文在閣下的司法管轄區發售或出售，以及該轉換須符合所有適用的最低初次投資額及最低持股額要求，並須符合投資者資格的準則。請參閱售股章程，了解各類別的特點的進一步詳情。茲提醒閣下就任何替代投資選項的適用性自行徵詢意見。

如屬贖回，贖回所得款項將根據售股章程的條文向閣下支付。如屬轉換，轉換所得款項將根據售股章程（及僅就香港股東而言，則為香港說明文件）的條文用作以適用的股價購買閣下指定的子基金股份。閣下股份的轉換或贖回均可能影響閣下的稅務狀況。因此，閣下應就各自的公民身份、居籍或居住在國家的任何適用稅項尋求獨立專業意見。

一般資料

僅就香港股東而言：售股章程、香港說明文件及各子基金的产品資料概要可於任何工作日（星期六及公眾假期除外）之一般辦公時間內在香港代表的辦事處免費索取，亦可於www.manulifeim.com.hk*閱覽。

閣下若有任何疑問或需要有關本通知書所載任何事項的任何進一步資料，可於一般辦公時間內隨時與本公司的執行人Citibank Europe plc, Luxembourg Branch聯絡（電話號碼：(352) 45 14 14 316或傳真號碼：(352) 45 14 14 850），或與香港分銷商宏利投資管理（香港）有限公司聯絡（電話號碼：(852) 2108 1110或傳真號碼：(852) 2810 9510），或聯絡閣下的銀行、分銷商或財務顧問。

代表

宏利環球基金
董事會

謹啟

* 此網站未經證監會審閱。

Manulife Global Fund
Société d'investissement à capital variable
Registered office: 31, Z.A. Bourmicht, L-8070 Bertrange
Grand Duchy of Luxembourg

This document is important and requires your immediate attention. If in doubt, you should seek independent professional advice. The Directors of the Company accept full responsibility for the accuracy of the information contained in this Notice and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief there are no other facts the omission of which would make any statement misleading.

Notice to Shareholders
("Notice")

5 May 2026

Dear Shareholder,

We are writing to inform you of certain changes to the Manulife Global Fund (the "**Company**").

Unless otherwise specified below, these changes will be reflected in the revised Prospectus of the Company (and where applicable and for Hong Kong Shareholders only, the revised Hong Kong Covering Document) (collectively, the "**Revised Prospectus**") to be dated July 2026. This Notice, which summarizes the changes for your ease of reference, should be read in conjunction with the current Prospectus of the Company dated April 2026 (and where applicable and for Hong Kong Shareholders only, the current Hong Kong Covering Document dated April 2026) (collectively, the "**Prospectus**") and, when available, the full text of the Revised Prospectus (which contains full and complete information about these changes).

Words and phrases used in this Notice shall, unless otherwise provided, have the same meanings as are ascribed to them in the Prospectus.

The board of directors of the Company (the "**Directors**" or the "**Board**") has decided that it is appropriate to implement the following changes with respect to the Company with effect from 10 July 2026 (the "**Effective Date**") (unless otherwise specified below):

1. *Repositioning of Asian Small Cap Equity Fund*

With a view to providing investors with a product with a thematic focus on the fast-growing innovation and technology sectors in order to capture more attractive returns, thus attracting more capital inflows from investors to further grow the size of the Sub-Fund, thereby enhancing fund management efficiency of the Sub-Fund, the investment objective of Asian Small Cap Equity Fund will be changed such that the Sub-Fund will aim to provide long-term capital growth for investors who hold a long term investment view and are prepared to accept significant fluctuations in the value of their investments, by investing primarily in equity and equity related securities of innovation and/or technology companies which are incorporated, located or listed, or have significant business interests, in the Asia Pacific region ("**Asia Pacific Innovation Companies**").

The investment policy will also be amended such that at least 70% of the Sub-Fund's net assets will be invested in equity and equity related securities of Asia Pacific Innovation Companies.

As a result, the Sub-Fund may have direct and/or indirect exposure to companies which are involved in, without limitation, the artificial intelligence value chain, biotechnology, and the

development and production of semiconductors and related equipment.

In addition, Shareholders should note the following key changes to the investment policy from the Effective Date onwards:

- (a) the Sub-Fund may invest up to 10% of its net assets in UCITS (undertaking for collective investment in transferable securities) and other UCIs (undertaking for collective investment) in accordance with Article 41(1)(e) of the 2010 Law;
- (b) the Sub-Fund will no longer be subject to any limitation on the portion of its net assets that may be invested in issuers of any market capitalisation (although securities of small and medium sized companies may represent, at times, more than 30% of the Sub-Fund's net assets due to the nature of its investment portfolio);
- (c) the Sub-Fund may, from time to time, invest more than 30% of its net assets in companies in the following sectors: information technology (including hardware and software), industrials, communication services, consumer discretionary and healthcare;
- (d) the Sub-Fund may, from time to time, invest more than 30% of its net assets directly in certain China A-Shares listed on the SSE or the SZSE via Shanghai-Hong Kong Stock Connect or Shenzhen-Hong Kong Stock Connect respectively; and
- (e) in times of extreme market volatility or during severe adverse market conditions, the Sub-Fund will have the flexibility to temporarily hold a substantial portion (up to 40%) of its assets in cash or cash equivalents, or invest in short-term money market instruments for the preservation of the value of the assets in the investment portfolio.

Following the changes to the investment objective and policy of the Sub-Fund (the "**Repositioning**"), the Sub-Fund will no longer compare its performance against nor will it be managed in reference to any benchmark.

As a result of the Repositioning, the Sub-Fund will be re-named as "**Asia Innovation Fund**" from the Effective Date, to reflect its new investment focus.

The Investment Manager is expected to commence the rebalancing of the Sub-Fund's portfolio approximately 2 weeks prior to the Effective Date (the "**Rebalancing Period**"). In light of the differences in the investment objective and policy of the Sub-Fund prior to and after the Repositioning, the proportion of assets which are subject to rebalancing is expected to be substantial. Investors should be aware that during the Rebalancing Period, the Sub-Fund may not be able to fully adhere to its current investment objective and policy.

The legal and administrative expenses that will be incurred in connection with the Repositioning described above are approximately USD35,000, which will be borne by Asian Small Cap Equity Fund.

2. Other miscellaneous updates

Please also take note of the following miscellaneous updates to the Revised Prospectus (and where applicable, the Hong Kong Covering Document):

- (a) enhancements of disclosures relating to potential conflicts of interests under Appendix II (*Statutory and General Information*) of the Prospectus;
- (b) change of registered office of Manulife Investment Management (Europe) Limited to 4th Floor, One Strand, London WC2N 5HR, United Kingdom;
- (c) change(s) to the board of directors of the Management Company; and
- (d) other enhancement and/or simplification of disclosures, administrative, editorial and/or clarificatory updates.

For Shareholders in Asian Small Cap Equity Fund only, if you do not agree with the changes described in section 1, you may apply to redeem or to switch your holding in Asian Small Cap Equity Fund to Shares of the same Class or Category in any other Sub-Fund(s), free of any switching charges or redemption charges, until 26 June 2026. In respect of other changes described above, if you do not agree with such changes, you may apply to redeem or to switch your holding in the relevant Sub-Fund(s) to Shares of the same Class or Category in any other Sub-Fund(s), subject to switching charges but free of redemption charges, in accordance with the Offering Documents. However, your bank or financial adviser may charge you fees in respect of such switching/redemption instructions. You are advised to contact your bank, distributor or financial adviser should you have any questions.

You can only switch your holding into Shares of the same Class or Category in the same Sub-Fund or another Sub-Fund, which is offered or sold in your jurisdiction pursuant to the provisions of the relevant offering documents, and such switch is subject to all applicable minimum initial investment amount and minimum holding requirements as well as investor eligibility criteria being complied with. Please refer to the Prospectus for further details of the features of each Class. You are reminded to seek your own advice as to the suitability of any alternative investment option.

In the case of redemption, the redemption proceeds will be paid to you in accordance with the provisions of the Prospectus. In the case of a switch, the conversion proceeds will be utilised to purchase Shares of Sub-Fund(s) specified by you at the share price(s) applicable in accordance with the provisions of the Prospectus (and for Hong Kong Shareholders only, the Hong Kong Covering Document). A switch or redemption of your Shares may affect your tax position. You should therefore seek independent professional advice on any applicable tax in the country of your respective citizenship, domicile or residence.

General

For Hong Kong Shareholders Only: The Prospectus, the Hong Kong Covering Document and the product key fact statements of each Sub-Fund are available during usual business hours on any weekday (Saturdays and public holidays excepted) at the office of the Hong Kong Representative free of charge and are also available at www.manulifeim.com.hk*.

Should you have any questions or require any further information about any of the matters set out in this Notice, you may contact the Administrator of the Company, Citibank Europe plc, Luxembourg Branch, at telephone number (352) 45 14 14 316 or fax number (352) 45 14 14 850 or the Hong Kong Distributor, Manulife Investment Management (Hong Kong) Limited, at telephone number (852) 2108 1110 or fax number (852) 2810 9510 at any time during normal business hours, or your bank, distributor or financial adviser.

Yours faithfully

Board

For and on behalf of Manulife Global Fund

* This website has not been reviewed by the SFC.